Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis

INTRODUCTION: Spinal muscular atrophy (SMA) is a genetic, neuromuscular disease caused by deletions and/or mutations in the survival of motor neuron 1 (SMN1) gene leading to reduced SMN protein levels. Nusinersen, an intrathecally administered antisense oligonucleotide therapy that increases SMN pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Fox, David, To, Tu My, Seetasith, Arpamas, Patel, Anisha M., Iannaccone, Susan T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988750/
https://www.ncbi.nlm.nih.gov/pubmed/36534265
http://dx.doi.org/10.1007/s12325-022-02376-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988750/
https://www.ncbi.nlm.nih.gov/pubmed/36534265
http://dx.doi.org/10.1007/s12325-022-02376-y

Ejemplares similares